Article Text


COPD and drugs: new and old concepts
P255 ATTAIN: twice-daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease
  1. D Singh1,
  2. P W Jones2,
  3. E D Bateman3,
  4. A Agusti4,
  5. R Lamarca5,
  6. G de Miquel5,
  7. C Caracta6,
  8. E Garcia Gil5
  1. 1Medicines Evaluation Unit, University of Manchester, Manchester, UK
  2. 2St George's, University of London, London, UK
  3. 3University of Cape Town, Cape Town, South Africa
  4. 4Thorax Institute, Hospital Clinic, Barcelona, and CIBER Enfermedades Respiratorias and Fundació Caubet-Cimera, Barcelona, Spain
  5. 5Almirall S.A., Barcelona, Spain
  6. 6Forest Research Institute, New Jersey, USA


Introduction and Objectives The Phase III ATTAIN study investigated the effect of two twice daily doses of aclidinium bromide, a second-generation, long-acting muscarinic antagonist with low systemic activity, in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Methods In this 24-week, double-blind study, patients were randomised (1:1:1) to receive aclidinium (200 μg, 400 μg) or placebo, twice daily. The primary endpoint was change from baseline in trough forced expiratory volume in 1 second (FEV1) at Week 24. Other study assessments at 24 weeks included: change from baseline in peak FEV1; percentage of patients achieving a clinically meaningful improvement in St George's Respiratory Questionnaire total score and Transition Dyspnoea Index; COPD symptoms as assessed by the EXACT Respiratory Symptoms score; exacerbation rate based on two definitions (healthcare resource utilisation and EXAcerbations of Chronic pulmonary disease Tool). Adverse events (AEs), clinical laboratory measures, vital signs and ECGs were also assessed.

Results A total of 819 patients were included in intention-to-treat (ITT) and safety populations. At Week 24, aclidinium 200 μg and 400 μg significantly improved trough FEV1 from baseline compared with placebo (by 99 ml and 128 ml, respectively; both p<0.0001). Aclidinium was significantly superior to placebo at Week 24 for all other study assessments (Abstract P255 table 1). Aclidinium was well tolerated and the incidence of anticholinergic AEs was low and similar to placebo. Changes in laboratory tests, vital signs and ECGs were similar between all groups.

Abstract P255 Table 1

Study assessments at Week 24 (ITT population)

Conclusion Aclidinium 200 μg and 400 μg twice daily provided clinically meaningful improvements in bronchodilation, health status, symptoms, breathlessness and exacerbation rate. Aclidinium was well tolerated with a similar safety profile for both doses; the incidence of AEs was similar to placebo.

Statistics from


  • Funding This study was supported by Almirall S.A., Barcelona, Spain, and Forest Laboratories, Inc., New York, USA.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.